Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ANTH is doing good , but when is it going to come out with some good news, because I can see this coming back down and take a turn if no news comes out, this company has been really bad about giving any news.
Anyone have any idea when some news will come out? the charts are looking good for a run but I have seen this one look good and still take a turn for the bad.
What do you all think about the SEC form 8-K - Changes in Registrants Certifying Accountant Financial Statements that came out today?
Insider Transaction: $ANTH Purchase at $0.53 per share of 100000 shares by Director Thompson David E. on 2013-06-24.
Here s the most recent & VERY bullish LifeSci report on $ANTH. They are also recognized coverage analysts by the co http://y.ahoo.it/n01mlQTs
I agree , there has been some good insight into there progress and positive new results and investors, so i also dont under stand why anth has not moved higher and keeps dropping. I am in at .66 and not sure howm much longer i can hold if this dosent turn positive soon. I dont want to jump out beucase i has seen the same thinkg happen when i was in pphm and kerx which i made money on so i dont want to jump out but anth does not make any sense right now.
I have seen this go from a 10$ stock go down to where it is now, where do you all think the bottom is going to be before it starts going back up ? Because I also think this is a 20$ or more stock
I thinking of getting in, do you guys think its a good time to get in ? i have been watching anth for a while and it looks like its a good time. After making 60% on kerx and missing out on more, i think anth will be the next kerx. Please let me know your thoughts?
Do you guys think that anth will go lower becuase of the offering that should end tomorrow before it starts to go back up again? The 1 year to 3 month charts look very bearish still.
All charts look good for next week , have a great weekend and hope everyone makes money next week.
I sold my Kerx with 60% gain and now i am all in on amd , i think this is going way up this year and is on a up trend already , take a look at the 1 year chart, i think all next week is a run up. Everyone have a good weekend
I just got off the phone with KERX and they said that the outcome is good but just taking a little longer to put the data together and will be released during the first part of January, they want to make sure all data is put together right the first time so when they file with the FDA for the new drug , it passes with no problems. I am a strong buy for kerx and will be adding more.
On the call with kerx and its going great, with great outcomes and outlooks.
This is stupid, and kerx should not be going this low
Whats up with this big drop today?
When is earnings for meet?
Anyone know why kerx is taking a dive now?
Can some one tell me why this stock took a 50% dive in march? Thanks
So how hi are thinking this will go on Monday or by the end of next week?
Does anyone know why emms is jumping today ? i see now news out there that would cause this. Please let me know if you know something. Thanks
So with the sell of kxow-fm radio, why is this stock not going up?
Emmis Sells KXOS/Los Angeles
August 23, 2012
Emmis pulls the trigger on the sale of Spanish Hits KXOS/Los Angeles to qualified designees of Mexico City-based Grupo Radio Centro. The price is $85.5 million, most of which will go to pay down Emmis debt.
Emmis recently announced it was negotiating to further extend the recently expired provision of the put and call agreement that gave GRC the right to buy the station for the $85.5 million figure -- after the August 8 deadline passed, the price was set to go up to $110 million, but the companies said at the time that they were still negotiating. According to an SEC filing, on August 20, that part of the agreement was extended through August 23, and now the sale has been made.
The original seven-year LMA gave GRC the right to purchase the station for $110 million during that term or for Emmis to require GRC to purchase the station for that amount when the term expired. But earlier this year Emmis and GRC adjusted the deal to offer the reduced price if a deadline was met.
So what every ones thinking on how high this might go? It still has a buy alert on it on a few other sites.
Hi is this board dead , and if not does anyone have insight on the near future for this stock ? This came on to my radar as a stock with a uptrend with a lot of promise.
This company and stock is bull shit, i was in long but there is no reason why this stock should be going down other then poor management and the ass holes manipulating the stock.
Stereotaxis, Inc. (STXS) today announced the Company has completed its previously announced private offering of common stock and private offering of unsecured, subordinated, convertible promissory debentures for gross proceeds of $18.5 million. Stereotaxis plans to use a portion of the net proceeds from the common stock offering to repay $7 million of the revolving Silicon Valley Bank (SVB) credit facility guaranteed by Alafi Capital and Sanderling Venture Partners and the balance of the proceeds of that offering and of the debenture offering for working capital, and for general corporate purposes.
Upon the closing of the financing transactions, the Company also announced an amendment to its credit agreement with SVB to extend its revolving credit facility to March 31, 2013. The revolving line of credit was decreased from $20 million to $13 million after pay down of $7 million of the guaranteed portion, but otherwise has similar terms and conditions to previous agreements with SVB.
I got a email from AEZS and here is what they said in the email:
We understand investors wanting more information on the Phase 3 trial results for perifosine in colorectal cancer and the Company’s plans for perifosine. As we stated on April 2, we are currently examining the data in further detail with our partners to get a better understanding of the results in order to move forward with a clear strategy that we will make known to the investment community in ordinary course.
As for the rest of the pipeline, our CEO stated in our March 28 PR that we expect to file an NDA for AEZS-130 as a diagnostic test for AGHD and initiate a Phase 3 trial in endometrial cancer with AEZS-108 over the course of 2012. He also said that we look forward to advancing earlier-stage key anticancer product candidates from our pipeline, including AEZS 112, AEZS 120 and Erk/PI3K inhibitors.
You can rest assured that we are working hard in order to establish a solid strategy for both our drug and business development activities moving forward.
Looking good for VIVUS Approval, here what they said on a Vivus msg board
: The panel's questions and remarks today were very encouraging. This includes member's of the FDA staff (including Dr. Coleman), and all of the Advisory Committee members.
In my opinion, the best news was that the Adcomm panel appears that they will model the new obesity drug cardiovascular assessment requirements after the current requirements for new diabetes drugs.
Currently, for new diabetes drugs, the company should calculate the upper bound of the two-sided 95 percent confidence interval for the estimated increased risk. The company calculates the point estimate for the risk ratio or hazard ratio and its corresponding two-sided 95% confidence interval. The upper bound of the 95% confidence interval represents a reasonable estimate of the worst case for increased CV risk.
For the CV data to support approvability of a new diabetes drug, this upper bound should be less than 1.80 with a reassuring point estimate. If this upper bound is between 1.30 and 1.80 and the overall risk-benefit analysis supports approval, a postmarketing CV trial generally will be required to show definitively that this upper bound is less than 1.30 (page 16 of the FDA Cardiovascular Assessment Adcomm Briefing Document).
For Qnexa, the upper limit of the confidence interval for Qnexa FDA MACE is 1.25 and the revised FDA MACE is 1.33 (page 110 of the FDA Qnexa Briefing Document). This is well below the 1.80 cutoff for a pre-approval CV outcomes trial. If this upper bound is between 1.30 and 1.80 and the overall risk-benefit analysis supports approval, a post-approval CV trial generally will be required to show definitively that this upper bound is less than 1.30.
Again, this is more support for a post-approval casrdiovascular assessment study for Qnexa. We shall see what the Adcomm says tomorrow.